(Q41333137)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

T Buclin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H R Brunner

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J Biollaz

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

1-29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003088-199732010-00001

31 October 2019

exact match

0 references

cites work

Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure

1 reference

12 December 2020

Effects of losartan on a background of hydrochlorothiazide in patients with hypertension

1 reference

12 December 2020

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

12 December 2020

Dose-response relationships of ACE inhibitors and angiotensin II blockers

1 reference

12 December 2020

Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers

1 reference

12 December 2020

The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753

1 reference

12 December 2020

Noninvasive blood pressure monitoring at the finger for studying short lasting pressor responses in man.

1 reference

12 December 2020

The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs

1 reference

12 December 2020

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans

1 reference

12 December 2020

Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist

1 reference

12 December 2020

Clinical pharmacokinetics and efficacy of renin inhibitors

1 reference

12 December 2020

Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems

1 reference

12 December 2020

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

1 reference

12 December 2020

Evolution of blockade of the renin-angiotensin system

1 reference

12 December 2020

Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide.

1 reference

12 December 2020

Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects

1 reference

12 December 2020

Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease

1 reference

12 December 2020

Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174

1 reference

12 December 2020

Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension

1 reference

12 December 2020

Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.

1 reference

12 December 2020

Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174

1 reference

12 December 2020

Saralasin in human hypertension: the early experience

1 reference

12 December 2020

Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview

1 reference

12 December 2020

Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.

1 reference

12 December 2020

Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.

1 reference

12 December 2020

Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension

1 reference

12 December 2020

Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

1 reference

12 December 2020

Angioedema induced by the angiotensin II blocker losartan

1 reference

12 December 2020

Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension

1 reference

12 December 2020

Renal hemodynamics in essential hypertensives treated with losartan

1 reference

12 December 2020

Angiotensin II receptors and angiotensin II receptor antagonists.

1 reference

12 December 2020

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man

1 reference

12 December 2020

Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects

1 reference

12 December 2020

Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension

1 reference

12 December 2020

The pharmacokinetics of losartan in renal insufficiency

1 reference

12 December 2020

Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension

1 reference

12 December 2020

Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy

1 reference

12 December 2020

Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension

1 reference

12 December 2020

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy

1 reference

12 December 2020

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

1 reference

12 December 2020

Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081

1 reference

12 December 2020

Losartan with hydrochlorothiazide in the treatment of hypertension.

1 reference

12 December 2020

Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I

1 reference

12 December 2020

Blood pressure effects of the angiotensin II receptor blocker, losartan

1 reference

12 December 2020

Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.

1 reference

12 December 2020

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1 reference

12 December 2020

Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring

1 reference

12 December 2020

Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects

1 reference

12 December 2020

In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions

1 reference

12 December 2020

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174

1 reference

12 December 2020

Open clinical studies on a new angiotensin II receptor antagonist, TCV 116

1 reference

12 December 2020

Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension. An overview

1 reference

12 December 2020

An overview of the clinical pharmacology of enalapril

1 reference

12 December 2020

Angiotensin receptor antagonists as a treatment for hypertension

1 reference

12 December 2020

How well have animal studies with losartan predicted responses in humans?

1 reference

12 December 2020

Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research.

1 reference

12 December 2020

Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

1 reference

12 December 2020

Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects

1 reference

12 December 2020

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects

1 reference

12 December 2020

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers

1 reference

12 December 2020

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog

1 reference

12 December 2020

Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629.

1 reference

12 December 2020

Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study

1 reference

12 December 2020

Does pharmacological profiling of a new drug in normotensive volunteers provide a useful guideline to antihypertensive therapy?

1 reference

12 December 2020

In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency

1 reference

12 December 2020

The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function

1 reference

12 December 2020

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients

1 reference

12 December 2020

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

1 reference

12 December 2020

Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers

1 reference

12 December 2020

The clinical potential of renin inhibitors and angiotensin antagonists

1 reference

12 December 2020

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

1 reference

12 December 2020

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.

1 reference

12 December 2020

Angiotensin receptor antagonists: focus on losartan

1 reference

12 December 2020

Inhibitors of the renin-angiotensin system.

1 reference

12 December 2020

Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy

1 reference

12 December 2020

Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease

1 reference

12 December 2020

A specific competitive antagonist of the vascular action of angiotensin. II

1 reference

12 December 2020

Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough

1 reference

12 December 2020

10.2165/00003088-199732010-00001

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9012554%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

31 October 2019

1053033865

0 references

Fatcat ID

release_kd6tcmmodnbzfcfhniknu6upvi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kd6tcmmodnbzfcfhniknu6upvi

24 November 2022

mapped directly with Wikidata item

1 reference